The Same Peptide, Injected and Swallowed: What Zenagamtide’s Two Trials Cost to Compare
Novo Nordisk ran one peptide two ways in the same trial network. The top oral arm received about nine times more drug per week than the injected arm — for a smaller effect. A rare direct measurement of the oral peptide tax.
On 30 July 2026 *The Lancet* published two phase 2 trials of zenagamtide, the peptide formerly called amycretin. Both ran under the same registration (NCT06542874), at the same 83 sites in 11 countries, over the same 36 weeks, drawn from the same pool of 915 screened participants. One gave the peptide by weekly injection; the other as a daily tablet. Comparisons that clean are rare. The top oral arm received roughly nine times more drug per week than the top injected arm and produced a smaller effect on the primary endpoint. Two weeks earlier, FDA approved Lipfendra (enlicitide), an oral macrocyclic peptide, on the strength of 56% and 59% LDL-C reductions. Both facts are about the same problem, and they point in opposite directions.
Condor Research supplies reference materials for laboratory research use only. Doses cited are from published clinical trials of investigational and approved medicines, reported as scientific findings. Nothing here is a recommendation to use any compound in humans. For the underlying mechanism — proteases, epithelial permeability, first-pass metabolism — see our explainer on why most peptides cannot be swallowed.
The two trials
Zenagamtide is a unimolecular agonist: a single peptide chain engaging the GLP-1 receptor, the amylin receptor and the calcitonin receptor. Novo Nordisk studied it in adults with type 2 diabetes on stable metformin, with or without an SGLT2 inhibitor, HbA1c 7.0–10.0%, BMI 23 to under 50. Primary endpoint in both trials: change in HbA1c from baseline to week 36.
| Subcutaneous, weekly | Oral, daily | |
|---|---|---|
| Participants | 262 (225 active, 37 placebo) | 186 active + 30 placebo |
| Dose groups | 0.4, 1.5, 5, 10, 20, 40 mg | 6, 25, 50 mg |
| HbA1c change, top dose | −1.7% | −1.4% |
| Treatment difference vs placebo, top dose | −1.56 pp (95% CI −2.05 to −1.07) | −1.09 pp (95% CI −1.59 to −0.59) |
| GI adverse events, top dose | — | 47% (vs 23% placebo) |
| PMID | 42532080 | 42532079 |
The arithmetic neither paper performs
The top subcutaneous arm received 40 mg per week. The top oral arm received 50 mg per day — 350 mg per week.
That is 8.75 times as much peptide, delivered by mouth, to produce a treatment difference of 1.09 percentage points rather than 1.56.
Two caveats keep that honest. These were dose-finding studies, not a head-to-head comparison, and neither arm was necessarily at its ceiling. And the oral arms were not obviously free to escalate: gastrointestinal adverse events ran at 26%, 41% and 47% across the three oral doses against 23% on placebo, a clear dose-dependent gradient. But the direction and the order of magnitude are not in dispute, and they match what is known about every oral peptide that has reached the clinic. Unmodified peptides show oral bioavailability well under 1–2%; even engineered ones remain low and highly variable — the same permeability barrier that governs whether a peptide reaches the brain operates here in a harsher form.
This is the number that “orally available” usually conceals. Not a yes-or-no property of a molecule, but a multiplier on how much of it you must make, formulate, ship and tolerate.
The other July result, pointing the other way
On 16 July 2026, two weeks before those papers appeared, FDA approved Lipfendra (enlicitide) — the first oral PCSK9 inhibitor, and a macrocyclic peptide. In the CORALreef Lipids and CORALreef HeFH phase 3 trials it reduced LDL-C by a placebo-adjusted 56% and 59% respectively at week 24, as a once-daily 20 mg tablet.
Set those two events side by side and they describe the two available strategies with unusual clarity.
Zenagamtide is the permeation-enhancer strategy. Take a peptide that behaves like a peptide, and engineer the environment around it — an enhancer that shields it from proteolysis and helps it across the epithelium. It works, and the trials above measure what it costs.
Enlicitide is the structural strategy. Do not protect the peptide; rebuild it so that it does not need protecting. Macrocyclisation closes the chain into a ring, removing the free termini that exopeptidases attack and rigidifying the backbone; combined with backbone modifications such as N-methylation, it can produce a molecule that survives the gut and crosses the epithelium on its own. Nature demonstrated the principle long ago — cyclosporine is a cyclic, heavily N-methylated undecapeptide, and it is orally bioavailable. Enlicitide is that principle applied deliberately to a designed target, and approved.
The trade-off is real in both directions. The enhancer route preserves the peptide’s pharmacology and pays in dose and variability. The macrocyclic route buys oral behaviour and pays in chemistry: the more a peptide is modified to survive digestion, the less it resembles the peptide it was derived from, in potency, selectivity and half-life — and macrocycles are harder and more expensive to synthesise.
There is also a third answer that removes the question entirely. Lilly’s orforglipron, marketed as Foundayo, is a non-peptide small molecule that agonises the GLP-1 receptor. No enhancer, no macrocycle, conventional manufacturing, ordinary tablet. Where a small molecule can do the job, the oral peptide problem does not need solving. The case for oral peptides rests on targets where it cannot — receptors with large, shallow, extended binding surfaces that small molecules struggle to cover, which is precisely the class that a three-receptor unimolecular agonist like zenagamtide addresses.
What to take from it
Route is part of the pharmacology, not a delivery detail. Comparing an oral result to a subcutaneous result as though they describe the same intervention is a category error, and a common one.
“Orally active” is a claim about a formulation, not a molecule. Remove the enhancer and the same peptide is not orally active in any useful sense. Any such claim should name the formulation, the compartment and the number.
Ask for the multiplier. The honest way to describe an oral peptide is the ratio in this article: how much more drug per unit time, for what fraction of the injected effect. Anyone claiming to have solved oral peptide delivery should be able to state it in that form. Novo Nordisk, to its credit, published the data that let anyone compute it.
Related reading
- Two Lancet phase 2 trials published on 30 July 2026 gave the same peptide by weekly injection and by daily tablet under the same registration, at the same 83 sites, over the same 36 weeks.
- The top oral arm received 350 mg per week against 40 mg per week subcutaneously — about 8.75 times more drug — for a smaller effect on the primary endpoint.
- Gastrointestinal adverse events rose with oral dose: 26%, 41% and 47% across the three arms, against 23% on placebo.
- Two weeks earlier FDA approved Lipfendra (enlicitide), an oral macrocyclic peptide, showing that the structural route to oral activity can work.
- “Orally active” describes a formulation in a compartment, not a molecule: remove the permeation enhancer and the same peptide is not orally active.
What is zenagamtide?
A single peptide that agonises the GLP-1, amylin and calcitonin receptors, formerly called amycretin. It is investigational and not approved anywhere.
How much more drug does the oral route need?
In these trials, roughly nine times more peptide per week than the subcutaneous arm, for a smaller effect on HbA1c.
Why can't peptides normally be swallowed?
Gastric and intestinal proteases digest them and the epithelium blocks large hydrophilic molecules. Unmodified peptides show oral bioavailability well under 1–2%.
Is any oral peptide approved?
Yes. Oral semaglutide relies on the permeation enhancer SNAC, and enlicitide, approved in July 2026, is an orally bioavailable macrocyclic peptide.